Leukotriene Receptor

Leukotriene Receptor

A family of powerful bioactive lipids known as leukotriene receptors (cys-LTs) act through two structurally distinct G protein-coupled receptors known as the CysLT1 and CysLT2 receptors. Important mediators of human bronchial asthma include the cysteinyl leukotrienes LTC4, LTD4, and LTE4. The second messenger system that the leukotriene receptor uses is phosphatidylinositol-calcium. It belongs to the superfamily of G protein-coupled receptors. When LTD4 activates CysLT1, smooth muscle contracts and grows more, there is oedema, eosinophil migration, and lung mucus layer damage. LTRAs, or leukotriene receptor antagonists, are a class of non-steroidal oral medications. They may also be known as bronchoconstriction preventors with anti-inflammatory properties. LTRAs function by preventing a chemical process that can result in airway inflammation.

Leukotriene Receptor related products

Structure Cat No. Product Name CAS No. Product Description
V84100 (5S,6S)-DiHETE 82948-87-6
V9950 Ablukast (Ro23-3544) 96566-25-5 Ablukast (Ro 23-3544) is a novel and potent leuktriene receptor antagonist with anti-asthmatic effects.
V75433 BLT2 antagonist-1 2069220-61-5 BLT2 agonist-1 (compound 15b) is a selective BLT2 antagonist that can inhibit the chemotaxis of CHO-BLT2 cells with IC50 of 224 nM.
V75431 BLT2 probe 1 2893803-05-7 BLT2 probe 1 (compound 13) is a fluorescent probe based on the synthetic BLT2 agonist CAY10583.
V75438 CP-96021 hydrochloride 167011-22-5 CP-96021 HCl is a balanced, potent orally bioactive leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist (inhibitor) with Kis of 34 nM and 37 nM, respectively.
V5319 CP105696 58081-99-3 CP-105,696 (CP105696; CP-105696) is an orally bioactive, potent and selective leukotriene B4 receptor (LTB4R) antagonist (IC50 against [3H]LTB4 = 5.6 nM for binding human neutrophils; IC50 = 9.7 nM & 30.3 nM, respectively using guinea pig spleen or mouse membranes) that targets LTB4R high- and low-affinity binding sites in a LTB4 non-competitive and competitive manner, respectively.
V75430 FPL-55712 free base 40785-97-5 FPL-55712 free base is a leukotriene receptor antagonist.
V51187 HAMI-3379 1245653-57-9 CysLT2 antagonist
V85212 JNJ-40929837 succinate 1191044-47-9
V75436 LTB4 antagonist 1 2929239-84-7 LTB4 antagonist 1 is a carboxamic acid compound that is a potent leukotriene B4 (LTB4) antagonist (inhibitor) with IC50 of 288 nM.
V75437 LTB4 antagonist 2 2929239-85-8 LTB4 antagonist 2 is a carboxamic acid compound that is an antagonist of leukotriene B4 (LTB4) and has potential anti-inflammatory activity.
V75432 LTB4 antagonist 3 2929239-87-0 LTB4 antagonist 3 (compound 24e) is a leukotriene B4 (LTB4) antagonist (inhibitor) with IC50 of 477 nM.
V4326 MK-571 sodium 115103-85-0 MK-571 sodium (L-660711; MK571) is a novel, potent, selective, orally bioactive antagonist of leukotriene D4 (LTD4) receptor with the potential to be used for pulmonary hypertension.
V41728 Montelukast Dicyclohexylamine 577953-88-9 Montelukast (MK0476) dicyclohexylamine is a potent, selective and orally bioactive cysteine leukotriene receptor 1 (CysLT1) antagonist.
V4387 MONTELUKAST SODIUM (MK0476) 151767-02-1 Montelukast sodium (also known as MK-476; trade names Singulair; Monteflo; Lukotas; Lumona) is a novel, potent, selective CysLT1 (leukotriene receptor) receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of seasonal allergies.
V75428 Montelukast-d6 (MK0476-d6 (free acid)) 1093746-29-2 Montelukast-d6 is the deuterium labelled form of Montelukast.
V75426 Montelukast-d6 sodium (MK0476-d6) 2673270-26-1 Montelukast-d6 (sodium) is the deuterated form of Montelukast (sodium).
V2451 Olsalazine Sodium (CJ-91B) 6054-98-4 Olsalazine Sodium (CJ-91B) is a potent anti-inflammatory prodrug, which consists of two 5-ASA moieties linked by an azo bond.
V75427 Piriprost potassium (U 60257B) 88851-62-1 Piriprost (U-60,257B) potassium is a leukotriene synthesis inhibitor.
V4685 Pranlukast 103177-37-3 Pranlukast is a potent, selective and competitive antagonist of cysteinyl leukotriene receptor-1 (CysLT1) Pranlukast with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM for inhibiting [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes, respectively.
Contact Us Back to top